A Randomized, Double Blind, Placebo Controlled Trial of Pioglitazone and Niacin Extended Release in Non-diabetic Patients With Metabolic Syndrome

Trial Profile

A Randomized, Double Blind, Placebo Controlled Trial of Pioglitazone and Niacin Extended Release in Non-diabetic Patients With Metabolic Syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Pioglitazone (Primary) ; Aspirin; Niacin
  • Indications Hypoalphalipoproteinaemia; Low HDL cholesterol; Metabolic syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2017 Status changed from recruiting to completed.
    • 05 Jun 2009 Pharmacodynamic results presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA), 2009.
    • 07 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top